Spine BioPharma

To kick off the American Academy of Orthopaedic Surgeons (AAOS) annual meeting, we participated in the Canaccord Genuity Group Inc. Genuity ?2025 Musculoskeletal Conference. This event gave our CEO, Marc Viscogliosi, the opportunity to not only present to esteemed industry leaders but also engage with innovative pioneers in fields ranging from orthopedics to regenerative medicine. It was exhilarating to learn all that is happening in this fast-paced environment. If you weren’t able to attend our presentation, you can watch it here: https://lnkd.in/e2BpcuXV #AAOS2025 #MusculoskeletalInnovation #BioPharma #DegenerativeDiscDisease

Spine BioPharma will be presenting at the Canaccord Genuity Group Inc.?2025 Musculoskeletal Conference on March 10th. Join us at 4:30 PM PST at the Westin San Diego where Marc Viscogliosi will showcase our pioneering work in addressing Degenerative Disc Disease through non-opiate, non-surgical therapies. Can't make it to San Diego? The presentation will be available via webcast on our website for 90 days following the event. #CanaccordGenuity #MusculoskeletalInnovation #BioPharma #DegenerativeDiscDisease

Spine BioPharma will be presenting at the Canaccord Genuity Group Inc.?2025 Musculoskeletal Conference on March 10th. Join us at 4:30 PM PST at the Westin San Diego where Marc Viscogliosi will showcase our pioneering work in addressing Degenerative Disc Disease through non-opiate, non-surgical therapies. Can't make it to San Diego? The presentation will be available via webcast on our website for 90 days following the event. #CanaccordGenuity #MusculoskeletalInnovation #BioPharma #DegenerativeDiscDisease

We are excited to be in San Francisco this week for #JPM2025 and to have presented at #BiotechShowcase 2025! The energy was electric, with thought-provoking discussions and valuable connections that will undoubtedly drive #biotech innovation forward.? ? In case you missed our #SpineBioPharma presentation on our innovative approach to addressing Degenerative Disc Disease (DDD) with non-opiate, non-surgical therapies, you can watch the full recording here:? https://bit.ly/3DUIppU

Spine BioPharma is presenting at Biotech Showcase 2025 on January 14th. Join us as our CEO, Marc Viscogliosi, presents a corporate overview and shares insights on our innovative approach to addressing Degenerative Disc Disease (DDD) with non-opiate, non-surgical therapies. Time: 3:00 PM PT Location: Hilton San Francisco Union Square Hotel, Franciscan-B Room #BiotechShowcase2025 #JPM2025 #HealthcareInnovation #DegenerativeDiscDisease

#ICYMI, the recording of Spine BioPharma’s presentation at the Piper Sandler 36th Annual Healthcare Conference is now available. Our CEO, Marc Viscogliosi gave an overview of: ? Who we are – Committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD). ? SB-01 – A first-in-class investigational DDD treatment offering the potential for pain relief, improved function, and potential to slow or stop disease progression. ? Future potential – Exploring SB-01 for additional indications beyond DDD. You can listen to the full presentation here: https://bit.ly/3BcYINV #SpineBioPharma #HealthcareInnovation #PiperSandlerConference #DegenerativeDiscDisease #SB01 ?

Spine BioPharma is presenting at the Piper Sandler 36th Annual Healthcare Conference on December 5th. Join us as our CEO, Marc Viscogliosi, shares insights on our innovative approach to addressing Degenerative Disc Disease (DDD) with non-opiate, non-surgical therapies. https://lnkd.in/dHC-A_AH #PiperSandlerConference #HealthcareInnovation #DegenerativeDiscDisease?

Honored to have Orthopedics This Week feature Spine BioPharma and our fully enrolled MODEL trial, a pivotal Phase 3 study for SB-01, the first intradiscal therapy targeting degenerative disc disease. This story reflects the incredible progress our team has made toward transforming the treatment options for millions of patients with chronic low back pain. Check out the article here: https://bit.ly/4evIexS #InnovationInSpineCare #DegenerativeDiscDisease?

Don’t miss Spine BioPharma’s CEO Marc Viscogliosi on November 6 at the Life Sciences Dealmaking Symposium 2024, hosted by McDermott Will & Emery Marc will be sharing valuable insights into how a strong regulatory strategy can boost deal value and mitigate risks, especially considering evolving FDA regulations. Join him and other industry leaders as they explore the future of life sciences dealmaking. Life Sciences Dealmaking Symposium 2024 #LSDS2024 #LifeSciences #Innovation #SpineBioPharma #RegulatoryStrategy #FDA #Dealmaking

We’re thrilled to announce that our Phase 3 MODEL clinical study of SB-01 has successfully enrolled over 400 patients across the U.S., marking a pivotal moment in our mission to develop non-opiate treatments for chronic low back pain. For too long, patients have faced limited options, often culminating in expensive surgeries and long recovery times. Our goal is to change that narrative and offer effective solutions that truly meet patient needs. Stay tuned for more updates! https://lnkd.in/eS--QWQg #degenerativediscdisease #ddd #lowbackpain #lowerbackpain #painmanagement #spinehealth #patientcare